In clinical practice, CT imaging and serum carcinoembryonic antigen (CEA) are now commonly used to assess response to treatment in NSCLC,7, 8 yet these approaches do not fully reflect the molecular and pathologic changes that occur in the tumor during treatment. Here, CEACAM5 is linked to non-small cell lung carcinoma.